Levosimendan Accord

Levosimendan, the active ingredient in Levosimendan Accord, is a calcium sensitizer presented as an injectable solution for intravenous use. It treats acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart failure, particularly acute decompensated heart failure. - Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Severe left ventricular dysfunction: provides inotropic support when conventional therapy is insufficient. - Post‑cardiac surgery low‑output syndrome: helps restore adequate systemic perfusion during the early postoperative period.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Hypotension: reduction in blood pressure, especially after rapid infusion. - Nausea or vomiting: gastrointestinal discomfort during or after administration. - Tachycardia: increased heart rate, usually dose‑related. - Dizziness: sensation of light‑headedness, often linked to blood pressure changes.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening irregular heart rhythms. - Myocardial ischemia: chest pain due to reduced coronary blood flow. - Severe hypotension: marked drop in blood pressure requiring intervention. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Levosimendan should be used with careful clinical monitoring. - Blood pressure monitoring: observe for hypotension during infusion. - Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders. - Renal function assessment: adjust therapy in severe renal impairment. - Hepatic impairment caution: consider reduced clearance in liver disease. - Contraindication in severe hypotension: avoid use when systolic pressure is markedly low. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP450 inhibitors (e.g., ketoconazole): can increase plasma concentrations. - Potassium‑channel blockers: additive effects on vascular tone.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte shifts and hypotension. - Beta‑blockers: may blunt the inotropic response. - ACE inhibitors or ARBs: combined effect on blood pressure needs observation.